TMCI — Treace Medical Concepts, Inc.

Summary of TMCI Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: $62.5 million, down 9% year-over-year, primarily due to a shift towards lower-priced products.
• Gross Margin: 80.6%, slightly down from 80.7% in Q4 2024.
• Operating Expenses: Increased to $56.3 million from $55.7 million in Q4 2024, reflecting restructuring charges and litigation expenses.
• Net Loss: $9.4 million ($0.15 per share), compared to a net loss of $0.5 million ($0.01 per share) in Q4 2024.
• Adjusted EBITDA: Loss of $6.2 million, down from a profit of $11.1 million in Q4 2024.
• Full Year Cash Usage: $27.3 million in 2025, a 46% reduction from $50.5 million in 2024.
• Cash Position: $48.4 million in cash and equivalents as of December 31, 2025, with an additional $115 million credit facility available.

2. Strategic Updates and Business Highlights

• Transformation: TMCI is evolving from a Lapiplasty-focused company to a comprehensive bunion solutions provider, launching multiple new bunion procedure innovations.
• Product Launches: Introduced three new bunion systems (Nanoplasty, Percuplasty 3D MIS, and SpeedMTP) aimed at capturing a larger share of the bunion surgery market.
• Surgeon Engagement: Over 25% of the surgeon base has adopted the new bunion systems within two quarters of their launch, contributing to mid-single-digit procedure volume growth in Q4.
• Market Positioning: TMCI aims to leverage its existing customer base to drive adoption of new products and expand its market share.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $200 million and $212 million, indicating a decline of 6% to 0% compared to 2025.
• Q1 2026 Expectations: Anticipated revenue decline of approximately 27% compared to Q4 2025, with gradual improvement expected in subsequent quarters.
• Adjusted EBITDA Outlook: Projected loss of $4 million to $6 million for 2026, with continued focus on reducing cash burn by approximately 50%.
• Product Launch Impact: Growth in the fourth quarter is expected to be driven by new product launches and improved case volumes.

4. Bad News, Challenges, or Points of Concern

• Market Headwinds: Continued softness in the foot and ankle market, particularly in elective procedures, has impacted overall case volumes.
• Product Mix Shift: The shift towards lower ASP products has contributed to revenue declines.
• Competitive Pressures: The market remains competitive, with TMCI needing to navigate challenges from both large and small competitors.
• Economic Conditions: Broader economic factors and consumer sentiment are expected to remain challenging in the near term.

5. Notable Q&A Insights

• Market Dynamics: CEO John Treace acknowledged that the foot and ankle market has been soft, with case deferrals impacting volume. However, TMCI has gained share with its new product offerings.
• Sales Force Focus: Treace emphasized that the sales force is well-prepared to promote the expanded product line, which addresses both existing and new surgeon needs.
• Long-term Growth Expectations: Management expressed confidence in achieving at least mid-single-digit growth rates in the long term, driven by product innovation and market share gains.
• Biologics Portfolio: The expansion into biologics is expected to enhance margins and provide additional revenue without negatively impacting operating margins.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, challenges, and insights from the Q&A session, providing a comprehensive overview of TMCI's current status and outlook.